1. Short title This Act may be cited as the Affordable Drug Manufacturing Act of 2018 . 2. Public manufacturing of pharmaceuticals Part A of title III of the Public Health Service Act ( 42 U.S.C. 241 et seq.) is amended by adding at the end the following: 310B. Manufacturing of drugs (a) Establishment of Office of Drug Manufacturing (1) In general There is established within the Department of Health and Human Services an office to be known as the Office of Drug Manufacturing (referred to in this section as the Office ). (2) Purpose The purpose of the Office is— (A) to increase competition, lower prices, and address shortages in the market for prescription drugs, including insulin; (B) to reduce the cost of prescription drugs to Federal and State health programs, taxpayers, and consumers; and (C) to increase patient access to affordable drugs. (3) Personnel (A) Director (i) In general The Office shall be headed by a Director, who shall be appointed by the President, by and with the advice and consent of the Senate. (ii) Compensation The Director shall be compensated at the rate prescribed for level III of the Executive Schedule. (B) Employees The Director of the Office, in consultation with the Secretary, may fix the number of, and appoint and direct, all employees of the Office. (C) Banned individuals (i) Drug company lobbyists No former registered drug manufacturer lobbyist— (I) may be appointed to the position of Director of the Office; or (II) may be employed by the Office during the 6-year period beginning on the date on which the registered lobbyist terminates its registration in accordance with section 4(d) of the Lobbying Disclosure Act of 1995 ( 2 U.S.C. 1603(d) ) or the agent terminates its status, as applicable. (ii) Senior executives of law-breaking companies No former senior executive of a covered entity (as defined in clause (iii))— (I) may be appointed to the position of Director of the Office